Yichen Sun

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Hydrogel microspheres for precision biomedicine: network engineering, microfabrication, and therapeutic applications.

Hydrogel microspheres for precision biomedicine: network engineering, microfabrication, and therapeutic applications.

Journal: RSC advances
Published: May 07, 2026

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Journal: Science translational medicine
Published: April 01, 2026

Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer.

Induction of cuproptosis via targeting mitochondrial metabolism using dPTBD with potent therapeutic activity against KRAS-driven cancer.

Journal: Cancer letters
Published: January 16, 2026

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.

Journal: Frontiers in immunology
Published: August 11, 2025

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 10, 2024

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 30, 2024

4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer.

4EBP1-mediated SLC7A11 protein synthesis restrains ferroptosis triggered by MEK inhibitors in advanced ovarian cancer.

Journal: JCI insight
Published: November 27, 2023

Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression.

Targeting AURKA to induce synthetic lethality in CREBBP-deficient B-cell malignancies via attenuation of MYC expression.

Journal: Oncogene
Published: August 22, 2023

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.

Journal: Gut
Published: June 13, 2023

Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.

Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma.

Journal: Cell death & disease
Published: March 08, 2023

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma.

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma.

Journal: MedComm
Published: December 08, 2022

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.

Journal: Clinical epigenetics
Published: November 03, 2022
Showing 1-12 of 19

Last Updated: 09/26/2026